Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Control Trial of Transarterial Chemotherapy (TAC) Versus Oral Thalidomide and Capecitabine in the Treatment of Unresectable Hepatocellular Carcinoma

NCT02240771 is registered in ClinicalTrials.gov with All India Institute of Medical Sciences as lead sponsor.

NCT NCT02240771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02240771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Control Trial of Transarterial Chemotherapy (TAC) Versus Oral Thalidomide and Capecitabine in the Treatment of Unresectable Hepatocellular Carcinoma
Lead sponsor
All India Institute of Medical Sciences
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 31, 2006
Completion date
March 31, 2015
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma